|
Treatment >
Nonsteroidal
Anti-Inflammatory Drugs |
|
|
Angiogenesis
|
|
|
|
Gately
S
The
contributions of cyclooxygenase-2 to tumor angiogenesis
Cancer Metastasis Rev 2000;19(1-2):19-27
|
|
Jones
MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS
Inhibition of
angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms
and implications for cancer growth and ulcer healing
Nat
Med 1999 Dec;5(12):1418-23
|
|
|
Glioblastoma
|
|
|
|
Amin R, Kamitani H, Sultana H, Taniura S, Islam A, Sho A,
Ishibashi M, Eling TE, Watanabe T
Aspirin
and indomethacin exhibit antiproliferative effects and induce apoptosis in T98G
human glioblastoma cells
Neurol Res. 2003
Jun;25(4):370-6
|
|
|
Grossman SA, Olson J, Batchelor T, Peereboom D,
Lesser G, Desideri S, Ye X, Hammour T, Supko JG
Effect of phenytoin on celecoxib pharmacokinetics in patients with
glioblastoma
Neuro Oncol. 2008 Feb 20; [Epub ahead of print]
 Abstract |
DBLinks | BL 7:5
|
|
|
Kesari
S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT,
Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM,
Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY.
Phase II study of temozolomide, thalidomide, and celecoxib for newly
diagnosed glioblastoma in adults
Neuro Oncol. 2008 Apr 10; [Epub ahead of print]
Abstract |
DBLinks | BL 7:8
|
|
|
S. Pannullo, S. Hariharan, J.
Serventi, R. Hayes, C. Balmaceda, J. Burton
Phase I/II trial of a twice-daily
regimen of temozolomide and celecoxib for treatment of relapsed/refractory
glioblastoma multiforme and anaplastic astrocytoma
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1549
|
|
|
S.
Pannullo, J. V. Serventi, C. Balmaceda, J. Burton
Temozolomide
plus celecoxib for treatment of malignant gliomas
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
455
|
|
|
Metastatic
Tumors
|
|
|
|
Leandro C. A. Cerchietti,
Marcelo R. Bonomi, Alfredo H. Navigante, Monica A. Castro, Maria E. Cabalar
and Berta M. C. Roth
Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as
a radiation sensitizer in patients with unresectable brain metastases
Journal
of Neuro-Oncology, 71(1):
73-81, January 2005. (Abstract+)
|
|
|
Non-Nervous
System Tumors
|
|
|
|
Arber N,
DuBois RN
Nonsteroidal
anti-inflammatory drugs and prevention of colorectal cancer
Curr Gastroenterol Rep 1999 Oct;1(5):441-8
|
|
Alshafie
GA, Abou-Issa HM, Seibert K, Harris RE
Chemotherapeutic
evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor
model
Oncol
Rep 2000 Nov-Dec;7(6):1377-81
|
|
|
Nasser
K Altorki, Roger S Keresztes, Jeffrey L Port, Douglas B Flieder, Cathy A
Ferrara, Mark W Pasmantier, Daniel M Libby, David Yankelevitz, Andrew J
Dannenberg
Celecoxib (Celebrex), a selective COX-2 inhibitor,
enhances the response to preoperative paclitaxel/carboplatin in early stage
non-small cell lung cancer
ASCO
Proceedings, 2002 Annual Meeting, Abstract No. 101
|
|
